193 related articles for article (PubMed ID: 28004985)
1. Cyclophosphamide enhances anti-tumor effects of a fibroblast activation protein α-based DNA vaccine in tumor-bearing mice with murine breast carcinoma.
Xia Q; Geng F; Zhang FF; Liu CL; Xu P; Lu ZZ; Xie Y; Sun B; Wu H; Yu B; Kong W; Yu XH; Zhang HH
Immunopharmacol Immunotoxicol; 2017 Feb; 39(1):37-44. PubMed ID: 28004985
[TBL] [Abstract][Full Text] [Related]
2. Improvement of anti-tumor immunity of fibroblast activation protein α based vaccines by combination with cyclophosphamide in a murine model of breast cancer.
Xia Q; Zhang FF; Geng F; Liu CL; Wang YQ; Xu P; Lu ZZ; Xie Y; Wu H; Chen Y; Zhang Y; Kong W; Yu XH; Zhang HH
Cell Immunol; 2016 Dec; 310():89-98. PubMed ID: 27545090
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of fibroblast activation protein α-based vaccines and adenovirus boost immunity by cyclophosphamide through inhibiting IL-10 expression in 4T1 tumor bearing mice.
Xia Q; Geng F; Zhang FF; Liu CL; Xu P; Lu ZZ; Zhang HH; Kong W; Yu XH
Vaccine; 2016 Aug; 34(38):4526-4535. PubMed ID: 27498213
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor effects of DNA vaccine targeting human fibroblast activation protein α by producing specific immune responses and altering tumor microenvironment in the 4T1 murine breast cancer model.
Xia Q; Zhang FF; Geng F; Liu CL; Xu P; Lu ZZ; Yu B; Wu H; Wu JX; Zhang HH; Kong W; Yu XH
Cancer Immunol Immunother; 2016 May; 65(5):613-24. PubMed ID: 27020681
[TBL] [Abstract][Full Text] [Related]
5. A DNA vaccine expressing an optimized secreted FAPα induces enhanced anti-tumor activity by altering the tumor microenvironment in a murine model of breast cancer.
Geng F; Guo J; Guo QQ; Xie Y; Dong L; Zhou Y; Liu CL; Yu B; Wu H; Wu JX; Zhang HH; Kong W; Yu XH
Vaccine; 2019 Jul; 37(31):4382-4391. PubMed ID: 31202521
[TBL] [Abstract][Full Text] [Related]
6. Alteration of the Tumor Stroma Using a Consensus DNA Vaccine Targeting Fibroblast Activation Protein (FAP) Synergizes with Antitumor Vaccine Therapy in Mice.
Duperret EK; Trautz A; Ammons D; Perales-Puchalt A; Wise MC; Yan J; Reed C; Weiner DB
Clin Cancer Res; 2018 Mar; 24(5):1190-1201. PubMed ID: 29269377
[No Abstract] [Full Text] [Related]
7. Epitope-based minigene vaccine targeting fibroblast activation protein α induces specific immune responses and anti-tumor effects in 4 T1 murine breast cancer model.
Zhang FF; Qiao Y; Xie Y; Liu C; Wu H; Wu JX; Yu XH; Kong W; Zhang HH
Int Immunopharmacol; 2022 Nov; 112():109237. PubMed ID: 36152535
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast activation proteins-α suppress tumor immunity by regulating T cells and tumor-associated macrophages.
Hou CM; Qu XM; Zhang J; Ding TT; Han W; Ji GC; Zhong ZH; Chen H; Zhang F
Exp Mol Pathol; 2018 Feb; 104(1):29-37. PubMed ID: 29273462
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model.
Wen Y; Wang CT; Ma TT; Li ZY; Zhou LN; Mu B; Leng F; Shi HS; Li YO; Wei YQ
Cancer Sci; 2010 Nov; 101(11):2325-32. PubMed ID: 20804499
[TBL] [Abstract][Full Text] [Related]
10. Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts.
Lee J; Fassnacht M; Nair S; Boczkowski D; Gilboa E
Cancer Res; 2005 Dec; 65(23):11156-63. PubMed ID: 16322266
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumour effects of a xenogeneic fibroblast activation protein-based whole cell tumour vaccine in murine tumour models.
Chen M; Xu G; Fan M; Jia H; Xiao L; Lang J
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):4182-4193. PubMed ID: 31722575
[TBL] [Abstract][Full Text] [Related]
12. Immunization of stromal cell targeting fibroblast activation protein providing immunotherapy to breast cancer mouse model.
Meng M; Wang W; Yan J; Tan J; Liao L; Shi J; Wei C; Xie Y; Jin X; Yang L; Jin Q; Zhu H; Tan W; Yang F; Hou Z
Tumour Biol; 2016 Aug; 37(8):10317-27. PubMed ID: 26842926
[TBL] [Abstract][Full Text] [Related]
13. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake.
Loeffler M; Krüger JA; Niethammer AG; Reisfeld RA
J Clin Invest; 2006 Jul; 116(7):1955-62. PubMed ID: 16794736
[TBL] [Abstract][Full Text] [Related]
14. Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant mice.
Gritzapis AD; Voutsas IF; Baxevanis CN
Cancer Immunol Immunother; 2012 Mar; 61(3):397-407. PubMed ID: 21928125
[TBL] [Abstract][Full Text] [Related]
15. A DNA vaccine targeting Fos-related antigen 1 enhanced by IL-18 induces long-lived T-cell memory against tumor recurrence.
Luo Y; Zhou H; Mizutani M; Mizutani N; Liu C; Xiang R; Reisfeld RA
Cancer Res; 2005 Apr; 65(8):3419-27. PubMed ID: 15833877
[TBL] [Abstract][Full Text] [Related]
16. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity.
Wang LC; Lo A; Scholler J; Sun J; Majumdar RS; Kapoor V; Antzis M; Cotner CE; Johnson LA; Durham AC; Solomides CC; June CH; Puré E; Albelda SM
Cancer Immunol Res; 2014 Feb; 2(2):154-66. PubMed ID: 24778279
[TBL] [Abstract][Full Text] [Related]
17. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
18. Curcumin combined with FAPαc vaccine elicits effective antitumor response by targeting indolamine-2,3-dioxygenase and inhibiting EMT induced by TNF-α in melanoma.
Jiang GM; Xie WY; Wang HS; Du J; Wu BP; Xu W; Liu HF; Xiao P; Liu ZG; Li HY; Liu SQ; Yin WJ; Zhang QG; Liang JP; Huang HJ
Oncotarget; 2015 Sep; 6(28):25932-42. PubMed ID: 26305550
[TBL] [Abstract][Full Text] [Related]
19. Treatment with cyclophosphamide supported by various dendritic cell-based vaccines induces diversification in CD4⁺ T cell response against MC38 colon carcinoma.
Wojas-Turek J; Szczygieł A; Kicielińska J; Rossowska J; Piasecki E; Pajtasz-Piasecka E
Int J Oncol; 2016 Feb; 48(2):493-505. PubMed ID: 26648160
[TBL] [Abstract][Full Text] [Related]
20. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein.
Huang X; Wong MK; Yi H; Watkins S; Laird AD; Wolf SF; Gorelik E
Cancer Res; 2002 Oct; 62(20):5727-35. PubMed ID: 12384531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
